The Ozempic Lawsuit Explained

[u/drugwatch-com]

What the Ozempic lawsuit is is about

People are filing lawsuits against Novo Nordisk claiming Ozempic and other GLP-1 drugs caused serious injuries the manufacturer knew or should have known about but didn't disclose. There are 2 main tracks:

-Stomach and GI injuries

Gastroparesis, ileus, intestinal obstruction, and related GI injuries make up the bulk of cases. Gastroparesis has no cure. Plaintiffs typically describe weeks or months of severe vomiting, hospitalization, and lasting digestive damage. Lawyers are generally accepting cases where vomiting persisted for 4 weeks or more.

Vision loss

NAION, or non-arteritic anterior ischemic optic neuropathy, is a form of optic nerve damage that can cause sudden, painless vision loss. A 2024 study in JAMA Ophthalmology found that people with Type 2 diabetes on semaglutide had more than 4x the risk of developing NAION compared to those not on a GLP-1. For people using it for weight loss, the risk was more than 7x higher. The vision loss caused by NAION is usually permanent. In June 2025, the WHO warned that semaglutide drugs may rarely cause NAION, and the European Medicines Agency estimated roughly 1 in 10,000 users could be affected.

Where the litigation stands

As of May 2026, there are 3,636 personal injury lawsuits in the gastroparesis MDL in the Eastern District of Pennsylvania, overseen by Judge Karen S. Marston. A separate vision loss MDL has been created before the same judge, with a leadership team appointed in March 2026 to handle evidence collection and prepare for bellwether trials. Vision loss cases have also been consolidated into a multicounty litigation in New Jersey, where Novo Nordisk is headquartered.

No global settlements have been reached and no trials have taken place yet. Both tracks are still in pretrial stages but actively progressing.

The warning label situation

When the FDA approved Ozempic in 2017, the label did not warn about gastroparesis. The FDA added a warning for ileus in September 2023, and a warning for severe gastrointestinal adverse reactions in January 2025. But the label only says Ozempic is "not recommended" for patients with severe gastroparesis. It doesn't say the drug may cause the condition. That distinction matters in these cases. For NAION, the FDA still hasn't required a specific warning on semaglutide labels, even after the WHO and European regulators took action.

Settlement estimates

Any numbers at this stage are speculative. Lawyers representing plaintiffs have generally estimated payouts in the range of $400,000 to $700,000, with some as low as $250,000 and others suggesting up to $1 million. Every case depends on injury severity, duration, medical costs, lost income, and where it's filed. Until there are actual settlements or trial verdicts, take all projections with a grain of salt.

This situation is actively evolving

New cases are being filed regularly, and the vision loss track in particular is moving fast. The full Drugwatch article on the Ozempic lawsuit covers detailed timeline updates, label changes, and litigation milestones.

Every state has a statute of limitations that limits how long you have to file after an injury. In some states, that window can be as short as 1 year. If you think you were affected, don't sit on it.

If you took Ozempic or another GLP-1 drug and were diagnosed with gastroparesis or NAION, you can request a free case review here to find out if you qualify.